8-K: Azenta Announces Fiscal Year 2024 Results, Plans Sale of B Medical Systems, and Appoints New CFO

Azenta reports its fiscal year 2024 results, including a plan to sell B Medical Systems, and the appointment of Lawrence Y. Lin as the new CFO.

Summary

• Azenta announced its financial results for the fourth quarter and fiscal year ended September 30, 2024.
• The company's fiscal year 2024 revenue was $656 million, a 1% decrease year-over-year, with a 2% organic revenue decline.
• However, the combined Sample Management Solutions and Multiomics businesses grew 4% organically for the year.
• Adjusted EBITDA for the full year was $49 million, with a margin of 7.5%, representing a 300 basis point improvement year-over-year.
• For the fourth quarter, revenue was $170 million, down 1% year-over-year, with a 2% organic revenue decline.
• The combined Sample Management Solutions and Multiomics business segments grew 5% organically in the fourth quarter.
• The company is pursuing the sale of its B Medical Systems segment to simplify its portfolio.
• Azenta has appointed Lawrence Y. Lin as its new Chief Financial Officer, succeeding Herman Cueto, who will remain as an advisor during the transition.
• The company expects organic revenue growth of 3% to 5% for fiscal year 2025, with an approximate 300 basis point expansion in Adjusted EBITDA margin.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positives like margin expansion and core business growth, the overall revenue decline, EPS loss, and the need to sell a business segment temper the positive aspects. The company is in a state of transition, which introduces uncertainty.

Positives

• The Sample Management Solutions and Multiomics businesses showed solid organic growth for both the full year and the fourth quarter.
• The company achieved a significant expansion in Adjusted EBITDA margin for the full year.
• Azenta is taking steps to simplify its portfolio by pursuing the sale of B Medical Systems.
• The appointment of a new CFO with extensive experience is a positive step for the company's financial leadership.
• The company's guidance for fiscal year 2025 indicates continued growth and margin expansion.

Negatives

• Overall revenue for fiscal year 2024 decreased by 1% year-over-year.
• The company experienced a 2% organic revenue decline for the full year.
• B Medical Systems revenue declined significantly, impacting overall results.
• The company reported a diluted EPS loss from continuing operations of ($3.09) for fiscal year 2024.
• The company's operating loss was $201 million for the full year.
• The company is reviewing the classification of amounts in the statements of cash flows which could impact previously issued statements.

Risks

• The company's ability to achieve its revenue growth targets for fiscal year 2025 is subject to market conditions and other factors.
• The sale of B Medical Systems may not be completed successfully or on favorable terms.
• The company's financial performance could be impacted by the ongoing review of its statements of cash flows.
• The company's transformation program may not deliver the expected cost reductions and margin improvements.
• The company faces risks related to global political and economic conditions, supply chain issues, and competition.

Future Outlook

Azenta expects organic revenue growth of 3% to 5% for fiscal year 2025, with an approximate 300 basis point expansion in Adjusted EBITDA margin.

Management Comments

• John Marotta, President and CEO, stated that the company ended fiscal 2024 strong, delivering core revenue growth in Sample Management Solutions and Multiomics and expanding margins.
• Mr. Marotta also mentioned the company's progress in the Transformation Program Ascend 2026 and its intention to carry that momentum forward.
• Mr. Marotta commented that Azenta offers a unique portfolio of differentiated products and services and occupies a strong position in the marketplace.
• Mr. Marotta expressed excitement about Lawrence Lin joining the team and acknowledged Herman Cueto's contributions.

Industry Context

This announcement reflects a strategic shift for Azenta, focusing on its core businesses while divesting a non-core segment. This is in line with industry trends where companies are streamlining operations to improve profitability and focus on high-growth areas. The life sciences sector is seeing increased demand for sample management and multiomics services, which Azenta is well-positioned to capitalize on.

Comparison to Industry Standards

• Azenta's organic revenue growth of 4% in its core businesses is comparable to other life science companies focusing on sample management and multiomics, such as Thermo Fisher Scientific and Danaher, which have also reported mid-single-digit growth in similar segments.
• The 300 basis point improvement in Adjusted EBITDA margin is a positive sign, indicating successful cost management and operational efficiencies, which is a key focus for companies in this sector.
• The decision to sell B Medical Systems is similar to moves by other diversified companies to divest non-core assets and focus on higher-margin businesses, such as Agilent's divestiture of its chemical analysis business.
• The appointment of a new CFO with experience in the life sciences and medical device industries is a common practice for companies seeking to strengthen their financial leadership, similar to recent CFO appointments at companies like Illumina and Bio-Rad.

Management Changes

Stakeholder Impact

• Shareholders may react positively to the focus on core businesses and margin expansion, but negatively to the overall revenue decline and EPS loss.
• Employees may experience changes due to the sale of B Medical Systems and the CFO transition.
• Customers of the Sample Management Solutions and Multiomics businesses may see continued investment and growth in those areas.
• Suppliers may need to adjust to changes in the company's portfolio and strategy.
• Creditors will be monitoring the company's financial performance and debt levels.

Next Steps

• The company will proceed with the sale of its B Medical Systems segment.
• Lawrence Lin will assume the role of CFO after the filing of the Annual Report on Form 10-K.
• Herman Cueto will transition to an advisor role to ensure a smooth transition.
• The company will focus on driving revenue growth and profitability in its core businesses.
• The company will continue to execute its Transformation Program Ascend 2026.

Key Dates

Keywords

Azenta, financial results, CFO, B Medical Systems, revenue growth, EBITDA margin, Sample Management Solutions, Multiomics, organic growth, portfolio simplification